Alpha-2-adrenoceptor-mediated inhibition of vagally induced gastric acid secretion with the anti-ulcer agent DQ-2511.
Effects of DQ-2511, a new peripherally acting anti-ulcer agent, on vagally induced gastric acid output and mucosal blood flow (MBF) were investigated in urethane-anesthetized rats with gastric fistula. Intravenous infusion of DQ-2511 (2 or 20 mg/kg/hr, for 30 min) reduced the vagally induced gastric acid output and MBF, and these inhibitory effects were abolished by pretreatment with phentolamine. The DQ-2511-induced inhibition of acid output was abolished with yohimbine, but not with prazosin. These observations suggest that DQ-2511 possesses the properties of an adrenergic alpha-2-adrenoceptor agonist. DQ-2511 presumably acts on adrenergic alpha-2-adrenoceptors located on the parasympathetic neurons in the gastric wall, thereby reducing the vagally-induced gastric acid output.
Yokotani
K
K
Department of Pharmacology, Kochi Medical School, Japan.
Okuma
Y
Y
Osumi
Y
Y
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D003000:Clonidine / Q000494:pharmacology; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects; D008297:Male; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000502:physiology; D012039:Regional Blood Flow / Q000187:drug effects; D014630:Vagus Nerve / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology
D000897:Anti-Ulcer Agents; D001549:Benzamides; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; C058308:ecabapide; D003000:Clonidine; D011224:Prazosin